同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评

智通财经01-07

智通财经APP讯，同源康医药-B(02410)发布公告，本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)拟纳入优先审评品种名单，拟定适应症为：具有表皮生长因子受体(EGFR)外显子19缺失 (19DEL)或外显子21(L858R)置换突变，并伴有中枢神经系统(CNS)转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2601804835?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-07 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601804835","market":"fut","top_or_hot":-1,"title":"同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评","media":"智通财经","content":"<div>\n<p>智通财经APP讯，同源康医药-B(02410)发布公告，本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)拟纳入优先审评品种名单，拟定适应症为：具有表皮生长因子受体(EGFR)外显子19缺失 (19DEL)或外显子21(L858R)置换突变，并伴有中枢神经系统(CNS)转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390102.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-07 22:49 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1390102.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，同源康医药-B(02410)发布公告，本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)拟纳入优先审评品种名单，拟定适应症为：具有表皮生长因子受体(EGFR)外显子19缺失 (19DEL)或外显子21(L858R)置换突变，并伴有中枢神经系统(CNS)转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390102.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1390102.html","article_id":"2601804835","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601804835","pubTimestamp":1767797362,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，同源康医药-B 发布公告，本公司在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心拟纳入优先审评品种名单，拟定适应症为：具有表皮生长因子受体外显子19缺失 或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。董事会亦已注意到本公司股份价格及成交量近期出现不寻常波动。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","09939":"开拓药业-B","TY":"Tri-Continental Corp","02410":"同源康医药-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Tongyuankang Pharmaceutical-B (02410): Idotinib mesylate tablets (TY-9591 tablets) are to be included in priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"02410":1.5,"TY":1.5,"09939":1.5},"content_text":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)拟纳入优先审评品种名单，拟定适应症为：具有表皮生长因子受体(EGFR)外显子19缺失 (19DEL)或外显子21(L858R)置换突变，并伴有中枢神经系统(CNS)转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。董事会亦已注意到本公司股份价格及成交量近期出现不寻常波动。经作出合理查询后，董事会确认，除上文所披露者外，截至本公告日期，其并不知悉导致有关波动的任何原因，或为避免本公司证券出现虚假市场而须予披露的任何资料，或根据香港法例第571章证券及期货条例第XIVA部须予披露的任何内幕消息。截至本公告日期，董事会确认本集团的业务经营正常稳定，其核心业务进展顺利，并无任何引起董事会和本公司管理层关注的须予披露的重大事项。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601804835","isCrawlerRequest":true}